{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:08:45Z","timestamp":1789117725887,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41030-026-00375-w","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:25:44Z","timestamp":1784190344000},"page":"917-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial"],"prefix":"10.1007","volume":"12","author":[{"given":"Doreen","family":"Addrizzo-Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lauterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fucile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Griffis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Teper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"4","key":"375_CR1","doi-asserted-by":"publisher","first-page":"00021-2023","DOI":"10.1183\/23120541.00021-2023","volume":"9","author":"PA Flume","year":"2023","unstructured":"Flume PA, Feliciano J, Lucci M, Wu J, Fucile S, Hassan M, et al. Pulmonary exacerbations in insured patients with bronchiectasis over 2 years. ERJ Open Res. 2023;9(4):00021-2023.","journal-title":"ERJ Open Res"},{"issue":"7","key":"375_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","volume":"11","author":"JD Chalmers","year":"2023","unstructured":"Chalmers JD, Polverino E, Crichton ML, Ringshausen FC, De Soyza A, Vendrell M, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med. 2023;11(7):637\u201349.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"375_CR3","doi-asserted-by":"publisher","first-page":"2401050","DOI":"10.1183\/13993003.01050-2024","volume":"65","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Mall MA, Chotirmall SH, O\u2019Donnell AE, Flume PA, Hasegawa N, et al. Targeting neutrophil serine proteases in bronchiectasis. Eur Respir J. 2025;65(1):2401050.","journal-title":"Eur Respir J"},{"issue":"6","key":"375_CR4","doi-asserted-by":"publisher","first-page":"2400518","DOI":"10.1183\/13993003.00518-2024","volume":"63","author":"H Choi","year":"2024","unstructured":"Choi H, McShane PJ, Aliberti S, Chalmers JD. Bronchiectasis management in adults: state of the art and future directions. Eur Respir J. 2024;63(6):2400518.","journal-title":"Eur Respir J"},{"issue":"173","key":"375_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0096-2024","volume":"33","author":"H Choi","year":"2024","unstructured":"Choi H, Xu J-F, Chotirmall SH, Chalmers JD, Morgan LC, Dhar R. Bronchiectasis in Asia: a review of current status and challenges. Eur Respir Rev. 2024;33(173):240096.","journal-title":"Eur Respir Rev"},{"issue":"9","key":"375_CR6","doi-asserted-by":"publisher","first-page":"e1269","DOI":"10.1016\/S2214-109X(19)30327-4","volume":"7","author":"R Dhar","year":"2019","unstructured":"Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health. 2019;7(9):e1269\u201379.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"375_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/resp.14059","volume":"26","author":"H Lee","year":"2021","unstructured":"Lee H, Choi H, Chalmers JD, Dhar R, Nguyen TQ, Visser SK, et al. Characteristics of bronchiectasis in Korea: first data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries. Respirology. 2021;26(6):619\u201321.","journal-title":"Respirology"},{"issue":"2","key":"375_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S2213-2600(24)00364-3","volume":"13","author":"J-F Xu","year":"2025","unstructured":"Xu J-F, Zheng H-Z, Lu H-W, Wang L-W, Wu B, Lv X-D, et al. Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study. Lancet Respir Med. 2025;13(2):166\u201376.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"375_CR9","doi-asserted-by":"publisher","first-page":"2200611","DOI":"10.1183\/13993003.00611-2022","volume":"61","author":"R Dhar","year":"2023","unstructured":"Dhar R, Singh S, Talwar D, Murali Mohan BV, Tripathi SK, Swarnakar R, et al. Clinical outcomes of bronchiectasis in India: data from the EMBARC\/Respiratory Research Network of India registry. Eur Respir J. 2023;61(1):2200611.","journal-title":"Eur Respir J"},{"issue":"12","key":"375_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04144-23","volume":"12","author":"A Konovalovas","year":"2024","unstructured":"Konovalovas A, Armalyt\u0117 J, Klimkait\u0117 L, Liveikis T, Jonaityt\u0117 B, Danila E, et al. Insights into respiratory microbiome composition and systemic inflammatory biomarkers of bronchiectasis patients. Microbiol Spectr. 2024;12(12):e0414423.","journal-title":"Microbiol Spectr"},{"issue":"2","key":"375_CR11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00054-2025","volume":"66","author":"KX Thng","year":"2025","unstructured":"Thng KX, Tiew PY, Mac Aog\u00e1in M, Narayana JK, Jaggi TK, Ivan FX, et al. Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study. Eur Respir J. 2025;66(2):2500054.","journal-title":"Eur Respir J"},{"issue":"9","key":"375_CR12","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.chom.2022.08.005","volume":"30","author":"L Li","year":"2022","unstructured":"Li L, Mac Aog\u00e1in M, Xu T, Jaggi TK, Chan LLY, Qu J, et al. Neisseria species as pathobionts in bronchiectasis. Cell Host Microbe. 2022;30(9):1311-27.e8.","journal-title":"Cell Host Microbe"},{"issue":"4","key":"375_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1055\/s-0041-1730891","volume":"42","author":"HR Keir","year":"2021","unstructured":"Keir HR, Chalmers JD. Pathophysiology of bronchiectasis. Semin Respir Crit Care Med. 2021;42(4):499\u2013512.","journal-title":"Semin Respir Crit Care Med"},{"issue":"10","key":"375_CR14","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","volume":"195","author":"JD Chalmers","year":"2017","unstructured":"Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med. 2017;195(10):1384\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"176","key":"375_CR15","doi-asserted-by":"publisher","first-page":"240179","DOI":"10.1183\/16000617.0179-2024","volume":"34","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Metersky M, Aliberti S, Morgan L, Fucile S, Lauterio M, et al. Neutrophilic inflammation in bronchiectasis. Eur Respir Rev. 2025;34(176):240179.","journal-title":"Eur Respir Rev"},{"issue":"20","key":"375_CR16","doi-asserted-by":"publisher","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","volume":"59","author":"K Doyle","year":"2016","unstructured":"Doyle K, L\u00f6nn H, K\u00e4ck H, Van de Po\u00ebl A, Swallow S, Gardiner P, et al. Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986). J Med Chem. 2016;59(20):9457\u201372.","journal-title":"J Med Chem"},{"issue":"6","key":"375_CR17","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/cpt.1053","volume":"104","author":"R Palm\u00e9r","year":"2018","unstructured":"Palm\u00e9r R, M\u00e4enp\u00e4\u00e4 J, Jauhiainen A, Larsson B, Mo J, Russell M, et al. Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects. Clin Pharmacol Ther. 2018;104(6):1155\u201364.","journal-title":"Clin Pharmacol Ther"},{"key":"375_CR18","unstructured":"Brinsupri (brensocatib). Prescribing Information. Insmed Incorporated; 2025. https:\/\/insmed.com\/pdf\/brinsupri_full_prescribing_information.pdf. Accessed 13 Aug 2025."},{"key":"375_CR19","unstructured":"Brinsupri. European Medicines Agency. EPAR\u2013summary of product characteristics; 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brinsupri-epar-product-information_en.pdf. Accessed 8 Dec 2025."},{"key":"375_CR20","unstructured":"Brinsupri. Medicines and Healthcare products Regulatory Agency. MHRA\u2013summary of product characteristics; 2026. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/2b4537b9ad4c64c188b673355af8885f15d448d0. Accessed 11 Mar 2026."},{"issue":"16","key":"375_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Burgel P-R, Daley CL, De Soyza A, Haworth CS, Mauger D, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2025;392(16):1569\u201381.","journal-title":"N Engl J Med"},{"key":"375_CR22","doi-asserted-by":"crossref","unstructured":"Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, et al. A phase 3, randomized, double-blind, placebo-controlled trial of brensocatib in patients with non-cystic fibrosis bronchiectasis\u2014the ASPEN trial. Abstract presented at the 7th World Bronchiectasis Conference; July 4\u20136, 2024; Dundee, Scotland.","DOI":"10.1016\/j.chest.2024.07.010"},{"issue":"12","key":"375_CR23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/jmg.36.12.881","volume":"36","author":"TC Hart","year":"1999","unstructured":"Hart TC, Hart PS, Bowden DW, Michalec MD, Callison SA, Walker SJ, et al. Mutations of the cathepsin C gene are responsible for Papillon-Lef\u00e8vre syndrome. J Med Genet. 1999;36(12):881\u20137.","journal-title":"J Med Genet"},{"issue":"2","key":"375_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.101357","volume":"64","author":"K Morimoto","year":"2026","unstructured":"Morimoto K, Chalmers JD, Burgel P-R, Daley CL, De Soyza A, Mauger D, et al. Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: analysis of the ASPEN trial. Respir Investig. 2026;64(2):101357.","journal-title":"Respir Investig"},{"issue":"4","key":"375_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1164\/rccm.202306-1093OC","volume":"209","author":"T Asakura","year":"2024","unstructured":"Asakura T, Okuda K, Chen G, Dang H, Kato T, Mikami Y, et al. Proximal and distal bronchioles contribute to the pathogenesis of non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2024;209(4):374\u201389.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"375_CR26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1183\/09031936.06.00131805","volume":"28","author":"V Poletti","year":"2006","unstructured":"Poletti V, Casoni G, Chilosi M, Zompatori M. Diffuse panbronchiolitis. Eur Respir J. 2006;28(4):862\u201371.","journal-title":"Eur Respir J"},{"issue":"1","key":"375_CR27","volume":"1","author":"X Lin","year":"2015","unstructured":"Lin X, Lu J, Yang M, Dong BR, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database Syst Rev. 2015;1(1):CD007716.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"375_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-2600(25)00019-0","volume":"13","author":"NS Zhong","year":"2025","unstructured":"Zhong NS, Qiu R, Cao J, Huang YM, Zhou H, Xu XX, et al. Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2025;13(5):414\u201324.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"375_CR29","doi-asserted-by":"publisher","first-page":"2401551","DOI":"10.1183\/13993003.01551-2024","volume":"65","author":"JD Chalmers","year":"2025","unstructured":"Chalmers JD, Shteinberg M, Mall MA, O\u2019Donnell AE, Watz H, Gupta A, et al. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study. Eur Respir J. 2025;65(1):2401551.","journal-title":"Eur Respir J"},{"issue":"1","key":"375_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/bcp.16249","volume":"91","author":"Y Tadayasu","year":"2024","unstructured":"Tadayasu Y, Sarubbi D, Furuichi T, Eleftheraki A, Nakamura S, Sauter W, et al. A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects. Br J Clin Pharmacol. 2024;91(1):199\u2013209.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"375_CR31","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cpdd.1094","volume":"11","author":"H Usansky","year":"2022","unstructured":"Usansky H, Yoon E, Teper A, Zou J, Fernandez C. Safety, tolerability, and pharmacokinetic evaluation of single and multiple doses of the dipeptidyl peptidase 1 inhibitor brensocatib in healthy Japanese and White adults. Clin Pharmacol Drug Dev. 2022;11(7):832\u201342.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00375-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:44:09Z","timestamp":1789116249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00375-w","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Doreen Addrizzo-Harris: clinical trial support to the institution from AN2 Therapeutics, Armata Pharmaceuticals, Chiesi, Boehringer Ingelheim, Hillrom, Insmed Incorporated, Novartis, Sanofi, Verona, and Zambon; consulting fees from AstraZeneca, Boehringer Ingelheim, Clarametyx, MannKind, Paratex, and Sanofi; and member of the data and safety monitoring board for MannKind. James D. Chalmers: grants and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Insmed Incorporated, and Zambon; a grant from Gilead; and personal fees from Chiesi and Novartis. Stefano Aliberti: grant support from GSK; consulting fees from AN2 Therapeutics, AstraZeneca, Boehringer Ingelheim, BRAHMS GmbH, Chiesi Farmaceutica SpA, CSL Behring GmbH, Fondazione Internazionale Menarini, GlaxoSmithKline SpA, Insmed Incorporated, Menarini, Moderna, MSD Italia Srl, Pfizer, PhysioAssist SAS, Verona Pharma PLC, Vertex Pharmaceuticals, and Zambon SpA; speaking fees from Boehringer Ingelheim, Fondazione Internazionale Menarini, GlaxoSmithKline SpA, Insmed Incorporated, Vertex Pharmaceuticals, and Zambon; data monitoring committee work with AstraZeneca, Insmed Incorporated, MSD Italia Srl, and Verona Pharma PLC. Pierre-R\u00e9gis Burgel: grants from GSK and Vertex, outside the submitted work; clinical trials advisory activity for AstraZeneca, Chiesi, GSK, Insmed Incorporated, MSD, Vertex, Viatris, and Zambon; substantial financial contributions to the budget of his institution from Association Vaincre la Mucoviscidose, Fili\u00e8re MUCO-CFTR, GSK, Soci\u00e9t\u00e9 Fran\u00e7aise de la Mucoviscidose, and Vertex. Pierre-R\u00e9gis Burgel is an editorial board member of Pulmonary Therapy. Pierre-R\u00e9gis Burgel was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Brian M. Morrissey: grants from the Cystic Fibrosis Foundation and clinical trial support to the institution from Boehringer Ingelheim, CSL Behring, Insmed Incorporated, US National Institutes of Health, and Vertex Pharmaceuticals. Xiangmin Zhang, Chunpeng Fan, Melanie Lauterio, Sebastian Fucile, Dianne Griffis, and Ariel Teper: employees and shareholders of Insmed Incorporated.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was conducted in accordance with the principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Council for Harmonisation, and applicable regulatory requirements. An institutional review board or independent ethics committee approved the protocol at each participating site (details provided as supplementary material). All participants provided their written informed consent before starting the study. Adolescents provided their signed assent if required per local requirements, and a parent or legal guardian provided their signed informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}